We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Diabetes

Journal Scan / Research · December 22, 2015

Canagliflozin as Add-On to Insulin in Type 1 Diabetes

Diabetes Care

 

Additional Info

Disclosure statements are available on the authors' profiles:

Diabetes Care
Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Insulin in Patients With Type 1 Diabetes
Diabetes Care 2015 Dec 01;38(12)2258-2265, RR Henry, P Thakkar, C Tong, D Polidori, M Alba

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading